CoChat

Nefazodone Treatment of Major Depression in Alcohol-Dependent Patients: A Double-Blind, Placebo-Controlled Trial

Roy-Byrne, Peter P., Pages, Kenneth P., Russo, Joan E., Jaffe, Craig, Blume, Arthur W., Kingsley, Elizabeth, Cowley, Deborah S., Ries, Richard K. · 2000 · Journal of Clinical Psychopharmacology
Cited by 74

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Depression is the most common comorbid psychiatric illness in patients with alcohol dependence. This double-blind study tested the efficacy of nefazodone versus placebo for the treatment of depression in actively drinking alcohol-dependent patients who were also participating in weekly group treatment for alcoholism. Sixty-four subjects with major depression disorder and alcohol dependence with a history of at least one prior episode of depression when not drinking were randomly assigned to receive 12 weeks of either nefazodone or placebo and participated in a weekly psychoeducational group on alcoholism. Subjects were assessed every 2 weeks for depression, anxiety, side effects, and drinking frequency. Subjects taking nefazodone were significantly more likely to complete the study (62%) than those taking placebo (34%). Analyses of covariance using drinks per week as a time-dependent covariate showed lower Hamilton Rating Scale for Depression scores at week 8 for end-point analysis and at weeks 8 and 12 for completers. The endpoint analysis demonstrated a significantly greater response in the nefazodone group (48%) than in the placebo group (16%). Both groups showed a similarly significant decrease in the average number of alcoholic drinks consumed per day over the course of the study. Although the number of adverse effects was significantly greater for the nefazodone group, there were no severe adverse events, and nefazodone was well tolerated. Nefazodone is a safe and effective antidepressant to use in a population of alcohol-dependent patients with depression who have a high degree of comorbidity. Nefazodone treatment was superior to placebo in alleviating depression in these patients but did not add any advantage over the psychoeducational group in terms of drinking outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00004714-200004000-00003

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 74

Metadata

Authors
Roy-Byrne, P. P., Pages, K. P., Russo, J. E., Jaffe, C., Blume, A. W., Kingsley, E., Cowley, D. S., & Ries, R. K.
Venue
Journal of Clinical Psychopharmacology
Published
2000-04
Volume
20
Issue
2
Pages
129-136
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2048324588
Cited by
74
References
3
FWCI
1.86
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nefazodone Treatment of Major Depression in Alcohol-Dependent Patients: A Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.1097/00004714-200004000-00003
The paper
Roy-Byrne, P. P., Pages, K. P., Russo, J. E., Jaffe, C., Blume, A. W., Kingsley, E., Cowley, D. S., & Ries, R. K. (2000). Nefazodone Treatment of Major Depression in Alcohol-Dependent Patients: A Double-Blind, Placebo-Controlled Trial. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-200004000-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.